1
|
Nagata T, Nakagawa K, Tsurumi F, Watanabe K, Endo T, Hata A. A case of novel NFKB2 variant with hypertensive emergency and nephrotic syndrome leading to CKD 5D. Pediatr Nephrol 2024:10.1007/s00467-024-06334-4. [PMID: 38587560 DOI: 10.1007/s00467-024-06334-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2023] [Revised: 02/11/2024] [Accepted: 02/13/2024] [Indexed: 04/09/2024]
Abstract
Nuclear factor kappa B (NF-κB) family plays a central role in the human immune system. Heterozygous variants in NFKB2 typically cause immunodeficiency with various degrees of central adrenal insufficiency, autoimmunity, and ectodermal dysplasia. No reported case has presented kidney failure as an initial symptom. Moreover, documentation of kidney involvement of this disease is limited. CASE DIAGNOSIS: A 2-year-old female who presented with dyspnea and hypertensive emergency in the setting of new-onset nephrotic syndrome with acute-on chronic kidney injury with resultant chronic kidney disease (CKD) was found to have a novel heterozygous N-terminal variant in NFKB2 (c.880del: p. Tyr294Ilefs*4) with mild hypogammaglobulinemia, but no adrenal insufficiency or ectodermal dysplasia. She became dialysis-dependent during her initial hospitalization and developed CKD stage 5D, requiring continued peritoneal dialysis. She is currently awaiting kidney transplantation. CONCLUSIONS: Whether nephrotic syndrome or kidney injury or failure is the primary symptom of this variant or secondary to some event remains unknown. Further case accumulation is warranted.
Collapse
Affiliation(s)
- Toru Nagata
- Department of Pediatrics, Medical Research Institute, Kitano Hospital PIIF, Tazuke-Kofukai, Osaka, Japan
| | - Kenji Nakagawa
- Department of Pediatrics, Medical Research Institute, Kitano Hospital PIIF, Tazuke-Kofukai, Osaka, Japan.
| | - Fumitoshi Tsurumi
- Department of Pediatrics, Medical Research Institute, Kitano Hospital PIIF, Tazuke-Kofukai, Osaka, Japan
| | - Ken Watanabe
- Department of Pediatrics, Medical Research Institute, Kitano Hospital PIIF, Tazuke-Kofukai, Osaka, Japan
| | - Tomomi Endo
- Department of Nephrology and Dialysis, Medical Research Institute, Kitano Hospital PIIF, Tazuke-Kofukai, Osaka, Japan
| | - Atsuko Hata
- Department of Pediatrics, Medical Research Institute, Kitano Hospital PIIF, Tazuke-Kofukai, Osaka, Japan
| |
Collapse
|
2
|
Tanno D, Saito K, Tomii Y, Nakatsuka Y, Uechi K, Ohashi K, Hidaka T, Yamadera Y, Hata A, Toyokawa M, Shimura H. A Multicenter Study on the Utility of Selective Enrichment Broth for Detection of Group B Streptococcus in Pregnant Women in Japan. Jpn J Infect Dis 2024; 77:68-74. [PMID: 37914290 DOI: 10.7883/yoken.jjid.2023.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2023]
Abstract
Universal screening for Streptococcus agalactiae, Group B Streptococcus (GBS), in pregnant women is important for the prevention of severe infectious diseases in neonates. The subculture method using selective enrichment broth significantly improves GBS detection rates in the United States; however, this method is not widely utilized in Japan mainly because of the lack of large-scale validation. Therefore, we aimed to validate the utility of the subculture method in collaboration with multiple facilities. A total of 1957 vaginal-rectal swab specimens were obtained from pregnant women at 35-37 gestational weeks from March 1, 2020, to August 30, 2020, at Fukushima Medical University Hospital, Aiiku Hospital, Kitano Hospital, and the University of the Ryukyus Hospital. Conventional direct agar plating, subculture using selective enrichment broth, and direct latex agglutination (LA) testing with incubated broth were performed for GBS detection, and discrepant results were confirmed using real-time PCR. The GBS detection rates for direct agar plating, subculture, and direct LA testing were 18.2% (357/1957), 21.6% (423/1957), and 22.3% (437/1957), respectively. The use of selective enrichment broth showed promise for GBS detection with high sensitivity and is therefore recommended for GBS screening to prevent GBS-related infectious diseases in neonates in Japan.
Collapse
Affiliation(s)
- Daiki Tanno
- Department of Clinical Laboratory Sciences, School of Health Sciences, Fukushima Medical University, Japan
- Department of Clinical Laboratory, Fukushima Medical University Hospital, Japan
- Department of Laboratory Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Kyoichi Saito
- Department of Clinical Laboratory, Fukushima Medical University Hospital, Japan
- Department of Laboratory Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Yasuaki Tomii
- Department of Clinical Laboratory, Aiiku Hospital, Japan
| | - Yukari Nakatsuka
- Department of Laboratory Medicine, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Japan
| | - Kohei Uechi
- Division of Clinical Laboratory and Blood Transfusion, University of the Ryukyus Hospital, Japan
| | - Kazutaka Ohashi
- Department of Clinical Laboratory, Fukushima Medical University Hospital, Japan
| | - Tomoo Hidaka
- Department of Hygiene and Preventive Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Yukio Yamadera
- Department of Clinical Laboratory, Fukushima Medical University Hospital, Japan
| | - Atsuko Hata
- Department of Pediatrics, Division of Infectious Diseases, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Japan
| | - Masahiro Toyokawa
- Department of Clinical Laboratory Sciences, School of Health Sciences, Fukushima Medical University, Japan
- Department of Clinical Laboratory, Fukushima Medical University Hospital, Japan
- Department of Laboratory Medicine, School of Medicine, Fukushima Medical University, Japan
| | - Hiroki Shimura
- Department of Clinical Laboratory, Fukushima Medical University Hospital, Japan
- Department of Laboratory Medicine, School of Medicine, Fukushima Medical University, Japan
| |
Collapse
|
3
|
Kobayashi K, Hata A, Imoto W, Kakuno S, Shibata W, Yamada K, Kawaguchi H, Sakurai N, Ito T, Uenoyama K, Takahashi T, Ueda S, Katayama T, Onoue M, Kakeya H. Evaluation of predictors of third-generation cephalosporin non-susceptibility and factors affecting recurrence or death in bacteremia caused by Citrobacter freundii complex , Enterobacter cloacae complex, and Klebsiella aerogenes. J Chemother 2024:1-11. [PMID: 38451087 DOI: 10.1080/1120009x.2024.2323326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Accepted: 02/20/2024] [Indexed: 03/08/2024]
Abstract
Factors involved in the susceptibility of third-generation cephalosporins (3GCs) to bacteremia caused by Citrobacter freundii complex, Enterobacter cloacae complex, and Klebsiella aerogenes were investigated based on a case-case-control design. Antimicrobial therapy administered 30 days prior to bacteremia and hospitalization within 90 days were common risk factors for the 3GC susceptible and 3GC non-susceptible groups, while hospitalization from an institution or another hospital was a specific risk factor for the 3GC non-susceptible group. We also attempted to examine the factors affecting the clinical outcome of bacteremia. Hospitalization more than 14 days before the onset of bacteremia was an independent factor indicating poor clinical outcome. In contrast, the implementation of source control was an independent predictor of successful treatment. Although a longer hospital stay before the onset of bacteremia was associated with worse clinical outcomes, implementation of source control may have contributed to improved treatment outcomes for bacteremia.
Collapse
Affiliation(s)
- Kazuhiro Kobayashi
- Department of Pharmacy, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
- Department of Infection Diseases, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
| | - Atsuko Hata
- Department of Infection Diseases, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
| | - Waki Imoto
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
| | - Shigeki Kakuno
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
| | - Wataru Shibata
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
| | - Koichi Yamada
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
| | - Hiroshi Kawaguchi
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
| | - Norihiro Sakurai
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
| | - Toshikazu Ito
- Department of Pharmacy, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
| | - Kazuya Uenoyama
- Department of Pharmacy, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
| | - Tamotsu Takahashi
- Department of Pharmacy, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
- Department of Infection Diseases, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
| | - Satoru Ueda
- Department of Pharmacy, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
- Department of Infection Diseases, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
| | - Toshiro Katayama
- Department of Medical Engineering, Faculty of Health Sciences, Morinomiya University of Medical Sciences, Osaka, Japan
| | - Masahide Onoue
- Department of Pharmacy, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
| | - Hiroshi Kakeya
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
- Research Centre for Infectious Disease Sciences, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
- Osaka International Research Centre for Infectious Disease, Osaka Metropolitan University, Osaka, Japan
| |
Collapse
|
4
|
Uchihara Y, Yamashita S, Watanabe H, Hata D, Hata A. Effects of short-term treatment with vibegron for refractory nocturnal enuresis. Pediatr Int 2023; 65:e15464. [PMID: 36572415 DOI: 10.1111/ped.15464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 12/20/2022] [Accepted: 12/23/2022] [Indexed: 12/28/2022]
Abstract
BACKGROUND Long-term nocturnal enuresis treatment leads to stress and lowered self-esteem for children and their parents. This study evaluated the short-term effectiveness and safety of vibegron (50 mg) for children with refractory nocturnal enuresis. METHODS A retrospective cohort study of children with therapy-resistant enuresis was conducted using data for July to December 2019. Enuresis frequency was recorded during 30 days before and after additional vibegron administration with prior treatment. We assessed the treatment effectiveness based on enuresis frequencies between before and after treatment with vibegron 50 mg. Statistical evaluation was performed using a paired t-test. RESULTS Among 29 children receiving vibegron, 14 (48.3%) exhibited a partial or complete response to the drug. Enuresis frequencies (mean ± standard deviation [SD]) were, respectively, 15.8 ± 9.2 and 9.5 ± 9.6 before and after treatment with vibegron during the observed 30 days. A statistically significant reduction in enuresis frequency was found (p < 0.001). Moreover, maximum mean±SD morning urine of 200 ± 62.9 mL before treatment with vibegron changed to 232 ± 76.6 mL after treatment. A significant increase in voiding volume in the early morning was found (p < 0.05). No drug-related severe adverse event was found. CONCLUSION Short-term treatment with vibegron is safe and effective for children with refractory enuresis.
Collapse
Affiliation(s)
- Yoshinori Uchihara
- Department of Pediatrics, Medical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, Osaka, Japan
| | - Sumie Yamashita
- Department of Pediatrics, Medical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, Osaka, Japan
| | | | - Daisuke Hata
- Department of Pediatrics, Medical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, Osaka, Japan
| | - Atsuko Hata
- Department of Pediatrics, Medical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, Osaka, Japan
| |
Collapse
|
5
|
Kobayashi K, Hata A, Imoto W, Kakuno S, Shibata W, Yamada K, Kawaguchi H, Sakurai N, Nakaie K, Nakatsuka Y, Ito T, Uenoyama K, Takahashi T, Ueda S, Katayama T, Onoue M, Kakeya H. The Clinical Evaluation of Third-generation Cephalosporins as Definitive Therapy for Enterobacter spp. and Klebsiella aerogenes Bacteremia. Intern Med 2022. [PMID: 36384899 PMCID: PMC10372282 DOI: 10.2169/internalmedicine.0612-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Background Third-generation cephalosporins (3GCs) may be susceptible in vitro to Enterobacter spp. and Klebsiella aerogenes. However, treatment with mainly fourth-generation cephalosporins or carbapenems is currently recommended. Diversification of antimicrobial agents in therapy is required to avoid the selection pressure of resistant organisms by broad-spectrum antimicrobial agents. Aims This study investigated the clinical efficacy of 3GC therapy for Enterobacter spp. and Klebsiella aerogenes bacteremia in a multicenter, retrospective, observational study. Methods Patients with Enterobacter spp. or Klebsiella aerogenes detected in blood cultures and treated with a susceptible antimicrobial agent were included in the study. Propensity score matching was performed to align patient background bases, and clinical outcomes between the 3GC and non-3GC groups were compared. Treatment success was defined as having no need for treatment escalation or the addition of other antimicrobial agents, no recurrence, or no death within 30 days. Results The study included 188 cases, of which 57 and 131 were included in the 3GC and non-3GC treatment groups, respectively; 53 patients in each group were matched by propensity score matching. There were no significant differences between groups in rates of switching to a susceptible antimicrobial or adding another agent, relapse within 30 days, or death within 30 days. In the 3GC group, source control was associated with favorable clinical outcomes. Conclusions Definitive 3GC therapy for susceptible Enterobacter spp. and Klebsiella aerogenes bacteremia is as clinically effective and valuable a targeted therapy as non-3GC therapy and can be implemented under conditions in which infection source control measures are in place.
Collapse
Affiliation(s)
- Kazuhiro Kobayashi
- Department of Pharmacy, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Japan
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Japan
- Department of Infection Diseases, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Japan
| | - Atsuko Hata
- Department of Infection Diseases, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Japan
| | - Waki Imoto
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Japan
| | - Shigeki Kakuno
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Japan
| | - Wataru Shibata
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Japan
| | - Koichi Yamada
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Japan
| | - Hiroshi Kawaguchi
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Japan
| | - Norihiro Sakurai
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Japan
| | - Kiyotaka Nakaie
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Japan
| | - Yukari Nakatsuka
- Department of Infection Diseases, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Japan
- Department of Clinical Laboratory, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Japan
| | - Toshikazu Ito
- Department of Pharmacy, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Japan
| | - Kazuya Uenoyama
- Department of Pharmacy, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Japan
| | - Tamotsu Takahashi
- Department of Pharmacy, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Japan
- Department of Infection Diseases, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Japan
| | - Satoru Ueda
- Department of Pharmacy, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Japan
- Department of Infection Diseases, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Japan
| | - Toshiro Katayama
- Department of Medical Engineering, Faculty of Health Sciences, Morinomiya University of Medical Sciences, Japan
| | - Masahide Onoue
- Department of Pharmacy, Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Japan
| | - Hiroshi Kakeya
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Japan
- Research Centre for Infectious Disease Sciences, Osaka Metropolitan University Graduate School of Medicine, Japan
| |
Collapse
|
6
|
Kuyama S, Yoshioka H, Kaneda H, Kataoka Y, Miura S, Katakami N, Yamanaka Y, Tamiya A, Yamada T, Yokoyama T, Hara S, Tanaka H, Fujisaka Y, Nakamura A, Azuma K, Namba M, Hata A, Sawa K, Ishikawa H, Kurata T. 330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
7
|
Inoue A, Hata A, Fifer S, Hasegawa K, Ando E, Takahashi M, Ordman R, Kasahara-Kiritani M. EP10.01-003 Non-Small Cell Lung Cancer Treatment Preferences Among EGFR Mutation Patients and Physicians in Japan. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
8
|
Sato Y, Fujiwara S, Hata A, Kida Y, Masuda T, Amimoto H, Matsumoto H, Miyoshi K, Otsuka K, Tomii K. 1545P A multicenter prospective observational study of pre-existing autoantibodies in patients with small cell lung cancer treated with ICI. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
9
|
Mamesaya N, Harada H, Hata A, Konno M, Nakamatsu K, Hayashi H, Yamamoto T, Saito R, Mayahara H, Kokubo M, Sato Y, Yoshimura K, Nishimura Y, Yamamoto N, Nakagawa K. 958P Intensity-modulated radiotherapy (IMRT)-adapted chemoradiotherapy (CRT) followed by durvalumab for locally advanced non-small cell lung cancer (NSCLC): A multicenter prospective observational study (WJOG12019L). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
10
|
Hazama D, Uemura T, Kenmotsu H, Meano K, Wakuda K, Teraoka S, Kobe H, Azuma K, Yamaguchi T, Masuda T, Yokoyama T, Otsubo K, Haratani K, Hayakawa D, Oki M, Takemoto S, Ozaki T, Okabe T, Hata A, Hashimoto H, Yamamoto N, Nakagawa K. EP16.02-005 Liquid Biopsy Detects Genomic Drivers in Non-small Cell Lung Cancer without EGFR Mutations by Single-plex Testing: WJOG13620L. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Tokito T, Hata A, Hara S, Tachihara M, Okada H, Tanaka H, Sato Y, Tabata E, Watanabe H, Takayama Y, Toyozawa R, Okamoto I, Wakuda K, Nakamura A, Shimokawa M, Yamamoto N, Nakagawa K. 1025P DOcetaxel (DOC) plus RAmucirumab (RAM) with pegylated Granulocyte-colONy stimulating factor (PEG-G-CSF) for elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial (DRAGON study: WJOG9416L). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
12
|
Morita R, Hata A, Ota T, Sumi T, Yoshioka H, Osugi J, Fujisaka Y, Mitsui M, Morita S, Katakami N. EP08.02-133 Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
13
|
Nakaoka Y, Yanagawa M, Hata A, Yamashita K, Okada N, Yamakido S, Hayashi H, Jayne D. POS0340 VASCULAR IMAGING IN PATIENTS WITH REFRACTORY TAKAYASU ARTERITIS TREATED WITH TOCILIZUMAB: ANALYSIS FROM A RANDOMIZED CONTROLLED TRIAL. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:In the TAKT study, a randomized controlled trial of tocilizumab (TCZ) in patients with refractory Takayasu arteritis (TAK) in Japan, the primary end point of time to relapse after induction of remission with glucocorticoid (GC) treatment showed a trend favoring TCZ over placebo (hazard ratio 0.41 [95.41% confidence interval, 0.15-1.10; p=0.0596]),1 but the double-blind period was too short for imaging evaluation.Objectives:To independently evaluate vascular imaging in a post hoc analysis of radiographs from the TAKT study.Methods:Computed tomography images from patients in the TAKT study were evaluated by three independent radiologists who were not involved in the original trial. Patients who received TCZ and had computed tomography images available (n=28) were included. Assessments were made in 22 arteries for the change from baseline in wall thickness (primary end point), dilatation/aneurysm, stenosis/occlusion, or wall enhancement for at least 96 weeks after the start of tocilizumab treatment. Patient-level assessments were also conducted.Results:Among 28 patients who received at least one dose of TCZ and for whom images were available, 86.7% of 22 arteries had improved/stable (no progression) wall thickness at week 96. The proportions of patients with no progressed, partially progressed, or newly progressed lesions were 57.1%, 10.7%, and 28.6% for wall thickness, and the proportions without progressed lesions were 92.9% for dilatation/aneurysm and 85.7% for stenosis/occlusion (Figure 1). Patients with newly progressed lesions, reflecting more refractory disease, were receiving glucocorticoid doses that could not be reduced below 0.1 mg/kg/day at week 96.Conclusion:Approximately 60% of patients with TAK treated with tocilizumab did not experience progression in wall thickness. Few patients experienced progressive dilatation/aneurysm or stenosis/occlusion. Wall thickness progression likely resulted from refractory TAK. Patients who experience this should be monitored regularly by imaging, and additional glucocorticoid or immunosuppressive treatment should be considered to avoid vascular progression.References:[1]Nakaoka Y et al. Ann Rheum Dis. 2018;77:348-354.Disclosure of Interests:Yoshikazu Nakaoka Consultant of: Roche/Genentech, Grant/research support from: Roche/Genentech, Masahiro Yanagawa Consultant of: Roche/Genentech, Akinori Hata Consultant of: Roche/Genentech, Katsuhisa Yamashita Employee of: Chugai Pharmaceutical Co., Ltd., Norihiro Okada Employee of: Chugai Pharmaceutical Co., Ltd., Shinji Yamakido Employee of: Chugai Pharmaceutical Co., Ltd., Hiromitsu Hayashi Consultant of: Roche/Genentech, David Jayne Consultant of: Roche/Genentech, Grant/research support from: Roche/Genentech
Collapse
|
14
|
Hata A, Hata M, Guo Y, Mei Z, Manafi A, Mahgoub B, Li D, Banerjee A, Yoshino I, Barker T, Krupnick A. Fibroblast Expression of Thy-1 Protects Grafts from Chronic Lung Allograft Dysfunction. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.1771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
15
|
Fujita M, Kusumoto S, Sugiyama M, Fujisawa T, Mizokami M, Hata A. Cost-effectiveness analysis for preventing hepatitis B virus reactivation-related death in Japan. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa166.566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
There is no worldwide standard recommendation for preventing hepatitis B virus (HBV) reactivation for patients with resolved infection treated with an anti-CD20 antibody for B-cell non-Hodgkin lymphoma. This study aims to compare the cost-effectiveness between two commonly used strategies to prevent HBV reactivation-related death.
Methods
The two strategies compared were prophylactic antiviral therapy (Pro NAT) and HBV DNA monitoring followed by on-demand antiviral therapy (HBV DNA monitoring) using entecavir (Entecavir, a generic drug for Baraclude). Effectiveness was defined as the prevention of death due to HBV reactivation and costs were calculated under the health insurance system of Japan as of April 2018 using Markov model. A cost-minimization analysis, one of the cost-effectiveness analyses, was applied, since the effectiveness was the same between the two strategies according to a meta-analysis. To consider the effect of uncertainty for each parameter, probabilistic sensitivity analysis (PSA) was performed. In the scenario analysis, costs were calculated using lamivudine (Zefix) or tenofovir alafenamide (Vemlidy) instead of entecavir. All analyses were done using TreeAge Pro 2019 (TreeAge Software, Inc., MA, USA).
Results
Estimated costs per patient during the 30 months after initiation of chemotherapy for lymphoma were 1,513 USD with Pro NAT and 1,265 USD with HBV DNA monitoring. A PSA revealed that HBV DNA monitoring was more consistently cost-effective compared with Pro NAT when some parameters were set randomly according to probability distributions. In our scenario analysis, costs of Pro NAT and HBV DNA monitoring were calculated as 2,762 and 1,401 USD using lamivudine, 4,857 and 1,629 USD using tenofovir alafenamide.
Conclusions
Our cost-effectiveness analysis shows that an HBV DNA monitoring strategy using entecavir should be recommended for preventing HBV reactivation-related death in Japan.
Key messages
Cost-effectiveness analysis demonstrated that HBV DNA monitoring was more cost-effective compared to Pro NAT; this result was consistent with PSA. HBV DNA monitoring strategy should be recommended to prevent HBV reactivation-related death for the patients with resolved HBV infection in Japan.
Collapse
Affiliation(s)
- M Fujita
- Department of Health Research, Chiba Foundation for Health Promotion and Disease Prevention, Chiba, Japan
- Genome Medical Sciences Project, National Center for Global Health and Medicine, Chiba, Japan
| | - S Kusumoto
- Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - M Sugiyama
- Genome Medical Sciences Project, National Center for Global Health and Medicine, Chiba, Japan
| | - T Fujisawa
- Department of Health Research, Chiba Foundation for Health Promotion and Disease Prevention, Chiba, Japan
| | - M Mizokami
- Genome Medical Sciences Project, National Center for Global Health and Medicine, Chiba, Japan
| | - A Hata
- Department of Health Research, Chiba Foundation for Health Promotion and Disease Prevention, Chiba, Japan
| |
Collapse
|
16
|
Sato Y, Shiota M, Sasaki K, Hata A, Hata D. Early therapy with corticosteroid and surfactant for acute idiopathic pulmonary hemorrhage in infants: Two case reports. Medicine (Baltimore) 2020; 99:e20281. [PMID: 32481307 PMCID: PMC7249888 DOI: 10.1097/md.0000000000020281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
RATIONALE Acute idiopathic pulmonary hemorrhage (AIPH) in infants is a rare condition, and a clear treatment protocol has not yet been established. PATIENT CONCERNS We report 2 infant cases of AIPH in a 3-month-old male and a 1-month-old female, who presented at an emergency room with epistaxis and respiratory distress. Both were immediately intubated, which revealed a bloody intratracheal aspirate. DIAGNOSIS Pulmonary hemorrhage was confirmed by X-ray and computed tomography imaging in both cases. The extensive evaluation revealed no specific etiology for the acute pulmonary hemorrhage, and AIPH was therefore diagnosed in both cases. INTERVENTIONS Intravenous methylprednisolone resulted in a rapid improvement in oxygenation and a reduction in high airway pressure during mechanical ventilation. Methylprednisolone was subsequently tapered off within 13 and 3 days in cases 1 and 2, respectively. In case 1, intratracheal administration of a surfactant also resulted in an immediate improvement in respiratory condition and the patient was extubated after 2 days; no effect was seen in case 2, and the patient was extubated after 10 days. OUTCOME Both infants recovered well without sequelae or further relapse after 23 and 71 months of follow-up, respectively. LESSONS Early administration of corticosteroid therapy and intratracheal administration of diluted surfactant should be considered for severe acute pulmonary hemorrhage in infants.
Collapse
|
17
|
Iki Y, Hata A, Fukuyama M, Yoshioka T, Watanabe K, Asari S, Hata D. Successful Conservative Treatment of Mycotic Pulmonary Artery Aneurysms Caused by MRSA Bacteremia. Pediatrics 2019; 144:peds.2019-0672. [PMID: 31624217 DOI: 10.1542/peds.2019-0672] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/02/2019] [Indexed: 11/24/2022] Open
Abstract
Mycotic pulmonary artery aneurysms (MPAAs) are rare and life-threatening with currently no recommended treatment strategies. In this report, we describe a successfully treated case of ventricular septal defect in an 11-month-old girl who developed bacteremia, infective endocarditis, and MPAA caused by methicillin-resistant Staphylococcus aureus (MRSA). We first started vancomycin, gentamycin, and panipenem-betamipron for infective endocarditis but switched to teicoplanin and arbekacin on day 3 after initiating treatment because bacteremia persisted, and vancomycin minimum inhibitory concentration was relatively high at 2 mg/L. Although we added clindamycin on day 5 and fosfomycin on day 7, MRSA bacteremia persisted, and we finally added daptomycin at 10 mg/kg per day on day 8, whereupon the bacteremia subsided within a day. Although the bacteremia subsided, the patient developed septic pulmonary embolisms and septic arthritis on her left knee. We continued daptomycin but switched the concomitant drug to linezolid, trimethoprim-sulfamethoxazole, and rifampicin on day 11. After several repeats of puncture and lavage of her knee joint, she became afebrile on day 16. Computed tomography scans taken on day 32 revealed right pulmonary artery MPAAs. She was treated with long-term multidrug therapy, and MPAAs were absent on subsequent computed tomography scans on day 184. Multidrug therapy mainly based on daptomycin could be a possible salvage therapy for refractory MRSA bacteremia with high vancomycin minimum inhibitory concentration. Conservative treatment should be selectively considered as a treatment option for clinically stable MPAA instead of surgical and endovascular treatment.
Collapse
Affiliation(s)
- Yoichi Iki
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka City, Osaka, Japan; and
| | - Atsuko Hata
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka City, Osaka, Japan; and
| | - Midori Fukuyama
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka City, Osaka, Japan; and
| | - Takakazu Yoshioka
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka City, Osaka, Japan; and
| | - Ken Watanabe
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka City, Osaka, Japan; and
| | - Seishi Asari
- Graduate School of Medicine, Osaka University, Suita City, Osaka, Japan
| | - Daisuke Hata
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka City, Osaka, Japan; and
| |
Collapse
|
18
|
Hata A, Satouchi M, Morita S, Ota Y, Urata Y, Kawa Y, Okada H, Mayahara H, Kokubo M, Akazawa Y, Uenami T, Tamiya M, Kunimasa K, Nakata K, Harada D, Nakamura A, Takase N, Katakami N, Negoro S. A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Ninomaru T, Hata A, Kokan C, Okada H. Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Kogure Y, Niwa T, Yoshioka H, Saka H, Hata A, Katakami N, Ozawa Y, Matsuo N, Hoshino T, Wakuda K, Kenmotsu H, Takahashi T, Nosaki K, Takenoyama M, Tajima M, Takahashi K, Ando M, Yamamoto N. P1.01-04 A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer: Results of NICE Salvage Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Akazawa Y, Nanjo S, Tamiya M, Hata A, Yamaguchi T, Kumagai T, Mori M, Katakami N. EP1.01-13 A Phase 2 Trial Assessing Osimertinib Activity Against Leptomeningeal Carcinomatosis in EGFR-Mutant Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Shiina Y, Suzuki H, Kaiho T, Hata A, Yamamoto T, Morimoto J, Sakairi Y, Wada H, Nakajima T, Yoshino I. Development of Novel Murine Antibody Mediated Rejection Model after Orthotopic Lung Transplant. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
23
|
Hata A, Ishioka T, Oishi K, Katayama T, Ohkubo T. Altered immunogenicity of 23-valent pneumococcal polysaccharide vaccine in elderly patients with diabetes who revealed lower responses to concomitant administration of BIKEN varicella zoster vaccine: Results of post hoc analysis of a randomized double-blind trial. J Diabetes Complications 2019; 33:243-248. [PMID: 30579569 DOI: 10.1016/j.jdiacomp.2018.11.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Revised: 10/18/2018] [Accepted: 11/05/2018] [Indexed: 10/27/2022]
Abstract
AIMS This double-blind randomized controlled study of 52 elderly patients with diabetes assessed cell-mediated immunity and safety of BIKEN varicella-zoster vaccine (BVZV). Cellular and humoral responses to VZV at 3 months after BVZV and 23-valent polysaccharide pneumococcal vaccine (PPSV23) vaccination elicited poor results. Post-hoc analyses assessed the effects of immunogenicity of PPSV23. METHODS Using standardized enzyme-linked immunosorbent assay, pneumococcal 6B and 23F serotype-specific immunoglobulin G (IgG)-binding antibody concentrations were measured in stored samples retrospectively before administration and 3 months after. Responders increased more than twofold in at least one serotype-specific IgG. RESULTS The geometric mean concentration ratio (GMCR) of serum anti-pneumococcal 6B IgG was 1.76 (95%C.I.: 0.58, 5.34) in patients receiving concurrent PPSV23 and BVZV, compared to 2.39 (95%C.I.: 0.53, 10.76) in patients receiving PPSV23 and placebo (P = .055). The GMCR of serum anti-pneumococcal 23F IgG was 2.54 (95%C.I.: 0.57, 11.43) in PPSV23/BVZV vaccinees compared to 3.34 (95%C.I.: 0.84, 12.92) in PPSV23/placebo vaccinees (P = .424). Responder rates, those who developed antibodies to either/both serotypes, were 68% in the BVZV group and 85% in the placebo group (P = .007). CONCLUSIONS Results suggest that concurrent administration of BVZV influenced humoral responses to PPSV23 in elderly subjects with diabetes.
Collapse
Affiliation(s)
- Atsuko Hata
- Department of Infectious Diseases, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan.
| | - Taisei Ishioka
- Environmental Hygiene Division, Takasaki General Public Health Center, 5-28 Takamatsucho, Takasaki, Gunma 370-0829, Japan
| | - Kazunori Oishi
- Infectious Disease Surveillance Center, National Institute of Infectious Diseases, 1-23-1 Toyama Shinjuku-ku, Tokyo 162-8640, Japan
| | - Toshiro Katayama
- Department of Engineering, Faculty of Health Sciences, Morinomiya University of Medical Sciences, 1-26-16 Nankokita Suminoe-ku, Osaka 559-8611, Japan
| | - Takayoshi Ohkubo
- Department of Hygiene and Public Health, Teikyo University School of Medicine, 2-11-1 Kaga Itabashi-ku, Tokyo 173-8605, Japan
| |
Collapse
|
24
|
Fujita M, Sugiyama M, Sato Y, Nagashima K, Takahashi S, Mizokami M, Hata A. Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan. J Viral Hepat 2018; 25:1312-1320. [PMID: 29770539 DOI: 10.1111/jvh.12933] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2018] [Accepted: 04/03/2018] [Indexed: 02/06/2023]
Abstract
This study aimed to determine the incidence and risk factors for hepatitis B virus (HBV) reactivation in patients with rheumatoid arthritis (RA) undergoing immunosuppressive therapy. The National Database of Japan, in which insurance claim data have been comprehensively accumulated, was utilized. The subjects were 76 641 RA patients who were plausibly initiated on immunosuppressive therapy from April 2013 to March 2014. Laboratory tests of the hepatitis B surface antigen, anti-hepatitis B virus surface antibody, and anti-hepatitis B virus core antibody were performed in 28.23%, 12.52% and 14.63% of patients, respectively, when the therapy was initiated. We found that HBV reactivation and fulminant hepatitis occurred in both the patients with and without HBV DNA monitoring, indicating insufficient monitoring in Japan during the study. The cumulative incidence of HBV reactivation over 24 months was 1.57% (95% confidence interval [CI] = 1.28%-1.92%) in the monitoring group, which consisted of those with resolved HBV infection. Glucocorticoid administration was a potent risk factor for HBV reactivation (hazard ratio [HR] = 1.70, 95% CI = 1.26-2.29, P = .001 in all subjects, and HR = 1.82, 95% CI = 1.18-2.81, P = .007 in the nonmonitoring group), although it was not statistically significant in the monitoring group (HR = 1.49, 95% CI = 0.99-2.26 and P = .057). No significant risk difference was observed between single administration of methotrexate and biological drugs.
Collapse
Affiliation(s)
- M Fujita
- Department of Public Health, Chiba University Graduate School of Medicine, Chiba City, Japan
| | - M Sugiyama
- Genome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa City, Japan
| | - Y Sato
- Department of Global Clinical Research, Chiba University Graduate School of Medicine, Chiba City, Japan
| | - K Nagashima
- Department of Global Clinical Research, Chiba University Graduate School of Medicine, Chiba City, Japan
| | - S Takahashi
- Clinical Research Center, Chiba University Hospital, Chiba City, Japan
| | - M Mizokami
- Genome Medical Sciences Project, National Center for Global Health and Medicine, Ichikawa City, Japan
| | - A Hata
- Department of Public Health, Chiba University Graduate School of Medicine, Chiba City, Japan
| |
Collapse
|
25
|
Fujita M, Hata A. Inequality within a community at a neighborhood level and mood disorder development in Japan. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky214.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Fujita
- Departiment of Public Health, Chiba University Graduate School of Medicine, Chiba-shi, Chiba, Japan
| | - A Hata
- Departiment of Public Health, Chiba University Graduate School of Medicine, Chiba-shi, Chiba, Japan
| |
Collapse
|
26
|
Marcoux N, Sequist L, Hata A, Banwait M, Dagogo-Jack I, Nagy R, Lanman R, Muzikansky A, Digumarthy S, Piotrowska Z. Real world cfDNA collection in EGFR-mutant NSCLC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy294.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Hata A, Katakami N, Nishino K, Mori M, Yokoyama T, Kurata T, Tachihara M, Takase N, Daga H, Kijima T, Morita S, Sakai K, Nishio K, Satouchi M, Negoro S. Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Harada D, Hata A, Okuda C, Kaji R, Masuda Y, Takechi Y, Kozuki T, Nogami N, Katakami N. Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Piotrowska Z, Isozaki H, Lennerz J, Digumarthy S, Gainor J, Marcoux N, Banwait M, Dias-Santagata D, Iafrate A, Mino-Kenudson M, Nagy R, Lanman R, Evans E, Clifford C, Wolf B, Hata A, Sequist L. MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.540] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Wada H, Toyoda T, Kaiho T, Ohashi K, Shina Y, Sata Y, Hata A, Yamamoto T, Morimoto J, Sakairi Y, Suzuki H, Nakajima T, Yoshino I. P2.16-44 Long-Term Outcome of Pulmonary Segmentectomy for c-IA Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
31
|
Kaiho T, Suzuki H, Ohashi K, Shiina Y, Sata Y, Toyoda T, Hata A, Yamamoto T, Morimoto J, Sakairi Y, Wada H, Nakajima T, Yoshino I. P1.16-36 Real-Time Ct Guided Video Assisted Thoracoscopic Partial Resection of Peripheral Small-Sized Lung Tumors. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Shiina Y, Nakajima T, Kaiho T, Ohashi K, Sata Y, Hata A, Toyoda T, Yamamoto T, Morimoto J, Sakairi Y, Wada H, Suziki H, Yoshino I. P3.16-09 High Preoperative D-Dimer Level Predicts Early Recurrence After Surgery for Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
33
|
Kiriu T, Tachihara M, Hata A, Hatakeyama Y, Nagano T, Yamamoto M, Kobayashi K, Ohnishi H, Katakami N, Nishimura Y. P1.01-48 Nab-Paclitaxel Plus Gemcitabine in Advanced NSCLC After Platinum-Based Chemotherapy: Final Results and Caveolin-1 Expression. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
Kono M, Akiyama M, Inoue Y, Nomura T, Hata A, Okamoto Y, Takeichi T, Muro Y, McLean W, Shimizu H, Sugiura K, Suzuki Y, Shimojo N. Filaggrin gene mutations may influence the persistence of food allergies in Japanese primary school children. Br J Dermatol 2018; 179:190-191. [DOI: 10.1111/bjd.16375] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- M. Kono
- Department of Dermatology; Nagoya University Graduate School of Medicine; 65 Tsurumai-cho Showa-ku, Nagoya 466-8550 Japan
| | - M. Akiyama
- Department of Dermatology; Nagoya University Graduate School of Medicine; 65 Tsurumai-cho Showa-ku, Nagoya 466-8550 Japan
| | - Y. Inoue
- Department of Pediatrics; Graduate School of Medicine, Chiba University; Chiba Japan
| | - T. Nomura
- Department of Dermatology; Hokkaido University Graduate School of Medicine; Sapporo Japan
| | - A. Hata
- Department of Public Health; Graduate School of Medicine, Chiba University; Chiba Japan
| | - Y. Okamoto
- Department of Otolaryngology, Head and Neck Surgery; Graduate School of Medicine, Chiba University; Chiba Japan
| | - T. Takeichi
- Department of Dermatology; Nagoya University Graduate School of Medicine; 65 Tsurumai-cho Showa-ku, Nagoya 466-8550 Japan
| | - Y. Muro
- Department of Dermatology; Nagoya University Graduate School of Medicine; 65 Tsurumai-cho Showa-ku, Nagoya 466-8550 Japan
| | - W.H.I. McLean
- Centre for Dermatology and Genetic Medicine; College of Life Sciences and College of Medicine, Dentistry and Nursing, University of Dundee; Dundee U.K
| | - H. Shimizu
- Department of Dermatology; Hokkaido University Graduate School of Medicine; Sapporo Japan
| | - K. Sugiura
- Department of Dermatology; Nagoya University Graduate School of Medicine; 65 Tsurumai-cho Showa-ku, Nagoya 466-8550 Japan
| | - Y. Suzuki
- Department of Public Health; Graduate School of Medicine, Chiba University; Chiba Japan
- Department of Education and Training; Tohoku Medical Megabank Organization, Tohoku University; Sendai Japan
| | - N. Shimojo
- Department of Pediatrics; Graduate School of Medicine, Chiba University; Chiba Japan
| |
Collapse
|
35
|
Hata A, Suzuki H, Oeda H, Nishii K, Kaiho T, Ohashi K, Shiina Y, Sata Y, Toyoda T, Sakairi Y, Tamura H, Fujiwara T, Wada H, Nakajima T, Yamada Y, Chiyo M, Yoshino I. Gene Expression Profiling in Murine Orthotopic Lung Transplantation Model of Chronic Lung Allograft Dysfunction (CLAD). J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
36
|
Hatakeyama Y, Tachihara M, Kiriu T, Hata A, Nagano T, Yamamoto M, Kobayashi K, Ohnishi H, Katakami N, Nishimura Y. 170P A phase II trial of nab-paclitaxel and gemcitabine in patients with non-small cell lung cancer previously treated with platinum based chemotherapy. J Thorac Oncol 2018. [DOI: 10.1016/s1556-0864(18)30444-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Kato K, Mizumoto H, Matsubara K, Hata A, Wachino JI, Arakawa Y, Hata D. Recurrence of Escherichia coli meningitis in a preterm infant and co-infection of echovirus 18. IDCases 2017; 10:135-137. [PMID: 29181300 PMCID: PMC5695537 DOI: 10.1016/j.idcr.2017.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 11/06/2017] [Accepted: 11/06/2017] [Indexed: 11/29/2022] Open
Abstract
Introduction Bacterial meningitis may relapse after adequate antibiotic treatment. In most cases, however, the pathophysiology cannot be identified. Presentation of case We describe a preterm infant with recurrent episodes of meningitis due to infection with an identical Escherichia coli strain both at birth and at 10 days after cessation of a 3 week course of appropriate antibiotic treatment. At the time of recurrence, the patient presented with fulminant severe cardiac failure due to acute myocarditis, coupled with a concurrent echovirus 18 infection (confirmed by stool culture and serological analysis). Conclusion Co-infection by echovirus may underlie recurrence of Escherichia coli meningitis in this case.
Collapse
Affiliation(s)
- Kentaro Kato
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
| | - Hiroshi Mizumoto
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
| | | | - Atsuko Hata
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
| | - Jun-Ichi Wachino
- Department of Bacteriology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Yoshichika Arakawa
- Department of Bacteriology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Daisuke Hata
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan
| |
Collapse
|
38
|
Piotrowska Z, Stirling K, Heist R, Mooradian M, Rizzo C, Digumarthy S, Lanuti M, Fintelmann F, Lennes I, Farago A, Gainor J, Azzoli C, Temel J, Mino-Kenudson M, Dias-Santagata D, Corcoran R, Shaw A, Hata A, Sequist L. OA 07.05 Serial Biopsies in Patients with EGFR-Mutant NSCLC Highlight the Spatial and Temporal Heterogeneity of Resistance Mechanisms. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Hata A, Takada MB, Nakashita R, Fukasawa K, Oshida T, Ishibashi Y, Sato Y. Stable isotope and
DNA
analyses reveal the spatial distribution of crop‐foraging brown bears. J Zool (1987) 2017. [DOI: 10.1111/jzo.12479] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- A. Hata
- Obihiro University of Agriculture and Veterinary Medicine Obihiro Japan
- Central Region Agricultural Research Center National Agriculture and Food Research Organization Tsukuba Japan
| | - M. B. Takada
- School of Agriculture and Life Sciences The University of Tokyo Tokyo Japan
| | - R. Nakashita
- Forestry and Forest Products Research Institute Tsukuba Japan
| | - K. Fukasawa
- National Institute for Environmental Studies Tsukuba Japan
| | - T. Oshida
- Obihiro University of Agriculture and Veterinary Medicine Obihiro Japan
| | - Y. Ishibashi
- Rakuno Gakuen University Ebetsu Japan
- Shimane Prefectural Government Western Agriculture and Forestry Promotion Center Shimane Japan
| | - Y. Sato
- Rakuno Gakuen University Ebetsu Japan
| |
Collapse
|
40
|
Tamiya M, Hata A, Katakami N, Kaji R, Yokoyama T, Toshihiko K, Inoue T, Kimura H, Yano Y, Tamuta D, Morita S, Negoro S. Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Wada H, Oheda H, Nishii K, Kaiho T, Ohashi K, Shina Y, Sata Y, Toyoda T, Hata A, Sakairi Y, Tamura H, Fujiwara T, Nakajima T, Suzuki H, Chiyo M, Yoshino I. P1.16-008 Near-Infrared Fluorescence-Guided Pulmonary Segmentectomy Following Endobronchial Indocyanine Green Injection. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
42
|
Lin J, Zhu V, Yoda S, Yeap B, Jessop N, Schrock A, Dagogo-Jack I, Gowen K, Stephens P, Ross J, Ali S, Miller V, Gainor J, Hata A, Iafrate A, Ou S, Shaw A. MA 07.07 Clinical Outcomes and ALK Resistance Mutations in ALK+ Non-Small Cell Lung Cancer According to EML4-ALK Variant. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Yanagi N, Fujiwara T, Hata A, Kondo K. Association between childhood socioeconomic status and sleep quality among old age in Japan. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx187.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- N Yanagi
- Graduate School of Medicine, Chiba University, Chiba, Japan
| | - T Fujiwara
- Tokyo Medical and Dental University, Tokyo, Japan
| | - A Hata
- Graduate School of Medicine, Chiba University, Chiba, Japan
| | - K Kondo
- Center for Preventive Medical Sciences, Chiba University, Japan
- Center for Gerontology and Social Science, Aichi, Japan
| |
Collapse
|
44
|
Hase T, Takeuchi S, Ando M, Hata A, Kenmotsu H, Fujiwara T, Shimizu S, Nagase K, Yoshimura K, Katakami N, Takahashi T, Hasegawa Y, Yano S. Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Sakairi Y, Nakajima T, Yonemori Y, Kaiho T, Ohashi K, Sata Y, Shiina Y, Toyoda T, Hata A, Tamura H, Fujiwara T, Wada H, Suzuki H, Chiyo M, Yoshino I. P2.12-006 Evaluation of New 25G Needle in EBUS-TBNA Comparing Conventional 22G Needle in Diagnosis for Nodal Metastasis of Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
46
|
Hata A, Okuda C, Kaji R, Katakami N. Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously T790M-negative patients? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Itoh N, Motokura K, Kumakura A, Hata D, Hata A. Herpes zoster meningitis in immunocompetent children: Two case reports and a literature review. Pediatr Int 2017; 59:1116-1118. [PMID: 29081071 DOI: 10.1111/ped.13362] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2017] [Revised: 06/20/2017] [Accepted: 07/06/2017] [Indexed: 11/30/2022]
Abstract
We encountered two cases of Herpes zoster (HZ) meningitis, a rarely occurring complication of HZ, in previously healthy children. One patient treated with i.v. acyclovir (ACV, 31 mg/kg/day) did not recover. His symptoms were relieved somewhat by increased ACV dosage, but it caused transient renal dysfunction. Another patient treated with i.v. ACV (30 mg/kg/day) recovered. Treatment for HZ meningitis in immunocompetent children has not been established. In a literature review, 80% of 20 patients were treated with the usual dose of ACV 15-30 mg/kg/day. The present cases suggest that a high dosage of ACV up to 60 mg/kg/day should be considered (while monitoring for side-effects) unless symptoms improve. In the review, one of every three vaccine-strain Varicella zoster virus (VZV) cases was severe, whereas the present cases resulted from wild type. Further investigations must examine different clinical characteristics of HZ meningitis caused by wild-type and vaccine-strain VZV.
Collapse
Affiliation(s)
- Naohiro Itoh
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka City, Osaka, Japan
| | - Kouji Motokura
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka City, Osaka, Japan
| | - Akira Kumakura
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka City, Osaka, Japan
| | - Daisuke Hata
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka City, Osaka, Japan
| | - Atsuko Hata
- Department of Pediatrics, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka City, Osaka, Japan
| |
Collapse
|
48
|
Ito M, Fujiwara S, Fujimoto D, Mori R, Yoshimura H, Hata A, Kohara N, Tomii K. Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient. Ann Oncol 2017; 28:2318-2319. [DOI: 10.1093/annonc/mdx252] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Takamatsu K, Marumo S, Fukui M, Hata A. Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease. J Microbiol Immunol Infect 2017; 50:541-544. [PMID: 28720319 DOI: 10.1016/j.jmii.2016.11.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Revised: 11/11/2016] [Accepted: 11/24/2016] [Indexed: 11/30/2022]
Abstract
We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4-40.6). Results confirm intravenous peramivir's usefulness.
Collapse
Affiliation(s)
- Kazufumi Takamatsu
- Department of Respiratory Medicine, Tazuke Kofukai Medical Research Institute Kitano Hospital, Japan
| | - Satoshi Marumo
- Department of Respiratory Medicine, Tazuke Kofukai Medical Research Institute Kitano Hospital, Japan; Department of Infectious Diseases, Tazuke Kofukai Medical Research Institute Kitano Hospital, Japan
| | - Motonari Fukui
- Department of Respiratory Medicine, Tazuke Kofukai Medical Research Institute Kitano Hospital, Japan
| | - Atsuko Hata
- Department of Pediatrics, Tazuke Kofukai Medical Research Institute Kitano Hospital, Japan; Department of Infectious Diseases, Tazuke Kofukai Medical Research Institute Kitano Hospital, Japan.
| |
Collapse
|
50
|
Piotrowska Z, Stirling K, Heist R, Campo M, Rizzo C, Digumarthy S, Lanuti M, Fintelmann F, Lennes I, Farago A, Gainor J, Azzoli C, Temel J, Mino-Kenudson M, Dias-Santagata D, Corcoran R, Shaw A, Engelman J, Hata A, Sequist L. Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.01.037] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|